3[3]Sievers EL,Larson RA,Stadmaner EA,et al.Efficacy and safety of gemtuzumab ozogamicin in patients with CD33 positive myeloid leukemia in fist relapse.J Clin oncol,2001,19(13):3244 -3254
4[4]Larson RA,Boogacrt m,Eestey E,et al.Antibody -targeted chemotherapy of older patients with acute myeloid leukemia in fist relapse using Mylotarg (gemtuzumab ozogamicin).Leukemia,2002,16(9):1627-1637
5[5]Miyakoshi S,K ami M,Yuji k,et al.Severe Pulmonary complications in jananese patients after bortezomib treatment for refractory multiple myeloma.Blood,2006,107(9):3492 -3494
6[6]Lo-Coco F,Cimino G,Breccia M,et al.Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.Blood,2004,104(7):1995-1999
1Murakami,Hiroski Handa H.New treatment strategy of multiple myeloma for care[J].Gan Kagaku Rycho,2006,33(4):417-423.
2Richardson P.Management of the relapsed/ refractory multiple myeloma; Strategies incorporating lenalidomide[J].Semin Hematol,2005,42(4 suppl 4):S9-15.
3Roccaro A M,Hideshima T,Raje N,et al.Bortezonib mediates antiangiogenesis in multiple myeloam via direct and indirect effects on endothelial cells[J].Cancer Res,2006,66(1):184-191.
4Yanamandra N,Colaco N M,Parguet N A,et al.Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia[J].Clin Cancer Res,2006,12(2):591-599.
5Greipp P.Treatment paradiagms for the new diagnosed patient with multiple myeloma[J].Semin Hematol,2005,42(4 suppl 4):S 16-21.
6Berenson J R,Jagannath S,Barlogie B,et al.Safety of prolong therapy with bortezomib in reapsed or refractory multiple myeloma[J].Cancer,2005,104(10):2141-2148.
7Miyakoshi S,Kami M,Yuji K,et al.Severe pulmonary complications in Jananese patients after bortezomib treatment for refractory multiple myeloma[J].Blood,2006,107 (9):3492-3494.
8Saunders G.Overview of drug therapy for multiple myeloma[J].Oncol Pharm Pract,2005,11(3):83-100.
9Sinha R,Kaufman J L,Lonial S.Novel treatment approaches for patients with multiple myeloma[J].Clin Lymphoma Myeloma,2006,6(4):281-288.
10Dubois D,Dhawan R,Yan de Velae H,et al.Descriptive and prognostic value of patients-reported outcomes.The bortezomib experience in relapsed and refractory multiple myeloma[J].J Clin Ocol,2006,24(6):976-982.
